237 related articles for article (PubMed ID: 18403061)
1. [B lymphocytes in Sjögren's syndrome].
Pers JO; Le Pottier L; Devauchelle V; Saraux A; Youinou P
Rev Med Interne; 2008 Dec; 29(12):1000-6. PubMed ID: 18403061
[TBL] [Abstract][Full Text] [Related]
2. B-cell tolerance breakdown in Sjögren's syndrome: focus on BAFF.
Varin MM; Le Pottier L; Youinou P; Saulep D; Mackay F; Pers JO
Autoimmun Rev; 2010 Jul; 9(9):604-8. PubMed ID: 20457281
[TBL] [Abstract][Full Text] [Related]
3. B cells in Sjögren's syndrome: from pathophysiology to diagnosis and treatment.
Cornec D; Devauchelle-Pensec V; Tobón GJ; Pers JO; Jousse-Joulin S; Saraux A
J Autoimmun; 2012 Sep; 39(3):161-7. PubMed ID: 22749831
[TBL] [Abstract][Full Text] [Related]
4. B-lymphocytes govern the pathogenesis of Sjögren's syndrome.
Youinou P; Saraux A; Pers JO
Curr Pharm Biotechnol; 2012 Aug; 13(10):2071-7. PubMed ID: 22208653
[TBL] [Abstract][Full Text] [Related]
5. B cell-targeted therapies in Sjögren's syndrome.
Tobón GJ; Pers JO; Youinou P; Saraux A
Autoimmun Rev; 2010 Feb; 9(4):224-8. PubMed ID: 19671451
[TBL] [Abstract][Full Text] [Related]
6. Secondary tumours in Sjögren's syndrome.
Kovács L; Szodoray P; Kiss E
Autoimmun Rev; 2010 Feb; 9(4):203-6. PubMed ID: 19602455
[TBL] [Abstract][Full Text] [Related]
7. BAFF-modulated repopulation of B lymphocytes in the blood and salivary glands of rituximab-treated patients with Sjögren's syndrome.
Pers JO; Devauchelle V; Daridon C; Bendaoud B; Le Berre R; Bordron A; Hutin P; Renaudineau Y; Dueymes M; Loisel S; Berthou C; Saraux A; Youinou P
Arthritis Rheum; 2007 May; 56(5):1464-77. PubMed ID: 17469105
[TBL] [Abstract][Full Text] [Related]
8. The role of M3 muscarinic acetylcholine receptor reactive T cells in Sjögren's syndrome: a critical review.
Sumida T; Tsuboi H; Iizuka M; Hirota T; Asashima H; Matsumoto I
J Autoimmun; 2014 Jun; 51():44-50. PubMed ID: 24397962
[TBL] [Abstract][Full Text] [Related]
9. Sequential therapy with belimumab followed by rituximab in Sjögren's syndrome associated with B-cell lymphoproliferation and overexpression of BAFF: evidence for long-term efficacy.
De Vita S; Quartuccio L; Salvin S; Picco L; Scott CA; Rupolo M; Fabris M
Clin Exp Rheumatol; 2014; 32(4):490-4. PubMed ID: 24802131
[TBL] [Abstract][Full Text] [Related]
10. B-cell populations and sub-populations in Sjögren's syndrome.
Hamza N; Bos NA; Kallenberg CG
Presse Med; 2012 Sep; 41(9 Pt 2):e475-83. PubMed ID: 22841377
[TBL] [Abstract][Full Text] [Related]
11. Sjögren's syndrome.
Delaleu N; Jonsson R; Koller MM
Eur J Oral Sci; 2005 Apr; 113(2):101-13. PubMed ID: 15819815
[TBL] [Abstract][Full Text] [Related]
12. Blood and salivary-gland BAFF-driven B-cell hyperactivity is associated to rituximab inefficacy in primary Sjögren's syndrome.
Cornec D; Costa S; Devauchelle-Pensec V; Jousse-Joulin S; Marcorelles P; Berthelot JM; Chiche L; Hachulla E; Hatron PY; Goeb V; Vittecoq O; Saraux A; Pers JO
J Autoimmun; 2016 Feb; 67():102-110. PubMed ID: 26688003
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic potential for B-cell modulation in Sjögren's syndrome.
Mariette X
Rheum Dis Clin North Am; 2008 Nov; 34(4):1025-33, x. PubMed ID: 18984420
[TBL] [Abstract][Full Text] [Related]
14. Artesunate inhibits Sjögren's syndrome-like autoimmune responses and BAFF-induced B cell hyperactivation via TRAF6-mediated NF-κB signaling.
Zhan T; Wang B; Fu J; Shao Y; Ye L; Shi H; Zheng L
Phytomedicine; 2021 Jan; 80():153381. PubMed ID: 33086170
[TBL] [Abstract][Full Text] [Related]
15. The future of B cell-targeted therapies in Sjögren's syndrome.
Cornec D; Saraux A; Devauchelle-Pensec V; Clodic C; Pers JO
Immunotherapy; 2013 Jun; 5(6):639-46. PubMed ID: 23725286
[TBL] [Abstract][Full Text] [Related]
16. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjögren's syndrome.
Thompson N; Isenberg DA; Jury EC; Ciurtin C
Rheumatology (Oxford); 2016 Sep; 55(9):1548-55. PubMed ID: 26790457
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis of Sjögren's syndrome and therapeutic consequences.
Mariette X; Gottenberg JE
Curr Opin Rheumatol; 2010 Sep; 22(5):471-7. PubMed ID: 20671520
[TBL] [Abstract][Full Text] [Related]
18. Immune regulation and B-cell depletion therapy in patients with primary Sjögren's syndrome.
Abdulahad WH; Kroese FG; Vissink A; Bootsma H
J Autoimmun; 2012 Aug; 39(1-2):103-11. PubMed ID: 22341852
[TBL] [Abstract][Full Text] [Related]
19. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome.
Groom J; Kalled SL; Cutler AH; Olson C; Woodcock SA; Schneider P; Tschopp J; Cachero TG; Batten M; Wheway J; Mauri D; Cavill D; Gordon TP; Mackay CR; Mackay F
J Clin Invest; 2002 Jan; 109(1):59-68. PubMed ID: 11781351
[TBL] [Abstract][Full Text] [Related]
20. [Pathophysiology of Sjögren's syndrome].
Mariette X
Ann Med Interne (Paris); 2003 May; 154(3):157-68. PubMed ID: 12910042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
